Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)

Navika D Shukla, Alexander F. M. Craig, MPhil, Brian Sworder, MD PhD, David M. Kurtz, MDPhD, Charles Macaulay, MSc, BA, Andrea Garofalo, BS, BA, Matthew J. Frank, MD PhD, Stefan Alig, MD, George Duran, BA, Youn H. Kim, MD, James Zehnder, MD, Crystal L. Mackall, MD, David B. Miklos, MD PhD, Maximilian Diehn, MD PhD, Michael S. Khodadoust, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-141655

Published: 2020

Journal Articles

Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling

Mohammad Shahrokh Esfahani, Stefan Alig, MD, David M. Kurtz, MD PhD, Joanne Soo, MD, Michael C. Jin, BS, Charles Macaulay, MSc, BA, Alexander F. M. Craig, MPhil, Andrea Garofalo, BS, BA, Chloe B. Steen, MSc, Florian Scherer, MD, Brian Sworder, MD PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 551.

https://doi.org/10.1182/blood-2019-132069

Published: 2019

Journal Articles

Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA

David M. Kurtz, MD PhD, Joanne Soo, MD, Stefan Alig, MD, Lyron Co Ting Keh, Charles Macaulay, Michael C. Jin, BS, Florian Scherer, MD, Emily G. Hamilton, BS, Chih Long Liu, PhD, Binbin Chen, PhD, Alexander F. M. Craig, MPhil, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 552.

https://doi.org/10.1182/blood-2019-131267

Published: 2019

Journal Articles

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Brian Sworder, MD PhD, David M. Kurtz, MD PhD, Charles Macaulay, MSc, BA, Matthew J. Frank, MD PhD, Stefan Alig, MD, Andrea Garofalo, BS, BA, Bita Sahaf, PhD, Mohammad Shahrokh Esfahani, Jay Y. Spiegel, MDFRCPC, Jean Oak, MD PhD, Sara Beygi, MD, Michael C. Jin, BS, Jacob J Chabon, Michael S. Khodadoust, MD PhD, Robbie G. Majzner, MD, Crystal L. Mackall, MD, Maximilian Diehn, MD PhD, David B Miklos, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 550.

https://doi.org/10.1182/blood-2019-129015

Published: 2019

Journal Articles

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

Stefan Alig, MD, Charles Macaulay, MSc, BA, David M. Kurtz, MD PhD, Ulrich Dührsen, Prof, MD PhD, Andreas Hüttmann, MD, Michael C. Jin, BS, Brian Sworder, MD PhD, Andrea Garofalo, BS, BA, Mohammad Shahrokh Esfahani, Joanne Soo, MD, Florian Scherer, MD, Alexander Craig, MPhil, Olivier Casasnovas, MD, Jason R. Westin, MD, Gianluca Gaidano, MD PhD, Davide Rossi, MD PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 491.

https://doi.org/10.1182/blood-2019-129283

Published: 2019

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial

Blood (2018) 132 (Supplement 1): 4096.

https://doi.org/10.1182/blood-2018-99-118000

Published: 2018

NARROW

Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)

Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling

Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial

Email alerts

ASH Publications

American Society of Hematology

Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA)

Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling

Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA

Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy

Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only